-
Vacaville生产基地是全球最大的生物制品生产设施之一。
-
此次收购显著扩大了龙沙 (Lonza) 在美国生物制品领域的版图，使其在美国西海岸占据重要地位，并进一步补充了龙沙 (Lonza) 现有的全球生产网络。
-
龙沙 (Lonza) 新增的大规模产能，可以满足持续的商业化生产的市场需求，并继续支持强大的分子管线走向商业化。
瑞士巴塞尔与美国Vacaville | 2024年10月1日
作为全球最大的医疗健康开发与生产组织之一，龙沙 (Lonza) 宣布已成功完成对罗氏位于美国加利福尼亚州Vacaville的基因泰克大规模生物制品生产基地的收购。收购价格为12亿美元。
以下为英文版新闻原文：
The Vacaville facility significantly extends Lonza’s capacity for mammalian manufacturing in the US, the world’s largest pharmaceutical market. It creates a significant West Coast commercial manufacturing presence close to San Francisco’s pharma and biotech hub, complementing Lonza’s existing East Coast manufacturing site in Portsmouth, New Hampshire, as well as its international network across Europe and Asia Pacific.
With a total bioreactor capacity of around 330,000 liters, the Vacaville site is one of the largest biologics manufacturing facilities in the world. This acquisition significantly extends manufacturing capacity for late-stage clinical and commercial products, and new molecules on the path to commercialization within the Lonza network. The site joins the Mammalian business unit within Lonza’s Biologics division, with more than 750 Vacaville colleagues now being employed directly by Lonza.
Wolfgang Wienand, CEO, Lonza, commented: “The successful acquisition of the Vacaville site marks a major milestone for Lonza, and for our commitment to deliver long-term value for our customers and shareholders. As the Vacaville site joins our Biologics division, we look forward to bringing new customer projects into the facility to meet sustained demand for commercial biologics manufacturing across our business. I am also delighted to welcome more than 750 highly skilled Vacaville colleagues into our global team, as they begin a new chapter with Lonza.”
The acquisition of the large-scale mammalian manufacturing site complements Lonza’s ongoing investments in large-scale bioconjugation in Visp (CH) and drug product manufacturing in Stein (CH), supporting its ability to meet demand for the large-scale, end-to-end manufacturing of complex biologics. Lonza plans to invest approximately CHF 500 million to further upgrade the facility and add capabilities to meet demand for the next generation of mammalian biologics therapies.
The products previously manufactured at the site will now be supplied by Lonza to Roche with committed minimum volumes over the medium term, phasing out over time as the site transitions to serve alternative customers.
关于龙沙集团
龙沙是全球制药、生物技术与营养市场的优秀合作伙伴。我们致力于助力客户推出创新药物辅助治疗一系列的疾病，成就更健康的世界。为达成这一使命，我们将先进生产制造、科学专业技术、卓越工艺及技术洞察力完美结合。为满足客户复杂的需求，我们的业务按四大板块划分为生物技术、小分子、细胞与基因、胶囊与健康原料。我们全方位的产品与服务帮助客户在医疗保健行业的发现与创新成果实现商业化。
1897年，龙沙诞生于瑞士的阿尔卑斯山脉地区。发展至今，业务已遍及全球五大洲。我们拥有约17,500名全职员工，由他们组成的高效团队及每一名员工都为我们的业务和所在地区及国家做出意义非凡的改变。2023年，公司销售额达67亿瑞士法郎。更多详情，请访问www.lonza.com
关于龙沙生物
作为全球生物制药CDMO行业的开拓者和领军者，龙沙（Lonza）拥有世界领先的专业技术以及生物制品全球上市申报和生产的成功经验。2023年，龙沙帮助客户开发和生产了超过600种临床前与临床大分子药物，以及超过55种商业化阶段大分子药物。